Lithium lev­els alert

Pharmacy Daily - - NEWS -

h^ of its nar­row ther­a­peu­tic in­dex, lithium’s risk of tox­i­c­ity is high, the Ther­a­peu­tic Goods Ad­min­is­tra­tion (TGA) re­minds health­care pro­fes­sion­als.

Lithium is mar­keted in Aus­tralia as Quilonum SR (450 mg sus­tained re­lease tablets) and Lith­i­carb (250 mg tablets).

“Fail­ure to recog­nise the early signs of tox­i­c­ity may lead to a de­lay in treat­ment and re­sult in poor pa­tient out­comes in­clud­ing, in the worst cases, death,” the TGA says.

Early symp­toms to look for can be sub­tle and am­bigu­ous, the TGA says, list­ing the com­mon ones, but any doubts mean re­fer­ral to the pa­tient’s doc­tor for test­ing.

Risk fac­tors are also iden­ti­fied in the TGA up­date.

Go to for de­tails.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.